FDA Warns Of Potential Safety Issues In Nephron Asthma Drug

Law360, New York (October 1, 2013, 3:58 PM EDT) -- The U.S. Food and Drug Administration issued a safety warning Monday over the potential health risks of Nephron Pharmaceuticals Corp.’s bronchial asthma drug Asthmanefrin, an over-the-counter inhaled solution that the agency said it has been receiving complaints about in the past year.

The FDA said since Asthmanefrin entered the OTC market in September 2012, the agency has received reports about symptoms of chest pain, nausea, increased blood pressure and heart rate, among other negative side effects from taking the drug, according to its safety announcement Monday....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.